Roche (OTCMKTS:RHHBY) Stock Rating Upgraded by Morgan Stanley

Roche (OTCMKTS:RHHBY) was upgraded by research analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating in a note issued to investors on Friday, Marketbeat reports. The firm currently has a $46.00 target price on the stock. Morgan Stanley’s target price indicates a potential downside of 10.92% from the company’s previous close.

A number of other research firms have also weighed in on RHHBY. Barclays raised shares of Roche from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Citigroup started coverage on shares of Roche in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. The Goldman Sachs Group upgraded shares of Roche from a “sell” rating to a “hold” rating in a report on Thursday, January 15th. Finally, TD Cowen restated a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $51.50.

Roche Trading Down 0.4%

OTCMKTS RHHBY opened at $51.64 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. Roche has a 1-year low of $35.07 and a 1-year high of $60.85. The business has a 50 day simple moving average of $52.80 and a two-hundred day simple moving average of $50.72.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Sentinel Trust Co. LBA bought a new stake in shares of Roche in the 3rd quarter worth about $878,000. Meritage Portfolio Management purchased a new stake in Roche in the 4th quarter worth about $4,372,000. Vestmark Advisory Solutions Inc. purchased a new stake in Roche in the 3rd quarter worth about $597,000. Confluence Investment Management LLC lifted its stake in Roche by 6.4% in the fourth quarter. Confluence Investment Management LLC now owns 18,649 shares of the company’s stock worth $962,000 after purchasing an additional 1,123 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC purchased a new position in shares of Roche during the third quarter valued at approximately $201,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.